Informations

This real-world study sheds light on the clinical outcomes of patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI). Conducted across Spain and Italy, the study evaluated 26 patients, offering valuable insights into survival outcomes and treatment-related adverse events in routine clinical practice.

The latest SEOM-GEMCAD-TTD clinical guidelines offer comprehensive updates on the adjuvant treatment of colon cancer, emphasizing the importance of personalized therapeutic strategies to optimize patient outcomes. These guidelines provide evidence-based recommendations tailored to tumor stage, molecular characteristics, and patient-specific factors, highlighting the shift towards precision medicine in oncology.

Oncology Frontier: Could you briefly introduce the current first-line treatment landscape for mCRC and the background of your study design? Dr. Yanhong Deng: The first-line treatment strategy for mCRC is…

1. What Can ERAS Bring to Surgical Care? A meta-analysis published in Clinical Nutrition explored the differences in outcomes between patients undergoing major elective open colorectal surgery under the ERAS…

Background of Research Selection and Recommendations Under the guidance of the Chinese Society of Clinical Oncology (CSCO), Peking University Library retrieved 6,435 publications on colorectal cancer from the SCI database.…

Recently, Dr. Yongsheng Li’s team from Chongqing University Cancer Hospital published a comprehensive review titled “Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies” in the high-impact journal MedComm (IF:…

The MORPHEUS Phase Ib/II trial explores a transformative approach in clinical research by integrating real-world data (RWD) as a hybrid control arm to supplement traditional randomized controlled trials (RCTs) in pancreatic ductal adenocarcinoma (PDAC).

A recent publication in Diagnostics delves into the critical comparison between two cutting-edge molecular techniques—Methyl-BEAMing and Droplet Digital PCR (ddPCR)—for detecting MGMT gene promoter hypermethylation. This biomarker plays a pivotal role in various cancers, particularly glioblastomas, as it helps predict patient response to alkylating agent-based chemotherapy.